|
1
|
Richardson MA: Complementary and
alternative therapy use in gynecologic oncology: implications for
clinical practice. Gynecol Oncol. 84:360–362. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Richart RM: A modified terminology for
cervical intraepithelial neoplasia. Obstet Gynecol. 75:131–133.
1990.PubMed/NCBI
|
|
3
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar
|
|
4
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
5
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
6
|
Toyoki H, Fujimoto J, Sato E, Sakaguchi H
and Tamaya T: Clinical implications of expression of
cyclooxygenase-2 related to angiogenesis in uterine endometrial
cancers. Ann Oncol. 16:51–55. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maher SG, Romero-Weaver AL, Scarzello AJ
and Gamero AM: Interferon: cellular executioner or white knight?
Curr Med Chem. 14:1279–1289. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shay JW and Wright WE: Role of telomeres
and telomerase in cancer. Semin Cancer Biol. 21:349–353. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kirkpatrick KL and Mokbel K: The
significance of human telomerase reverse transcriptase (hTERT) in
cancer. Eur J Surg Oncol. 27:754–760. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cohen SB, Graham ME, Lovrecz GO, Bache N,
Robinson PJ and Reddel RR: Protein composition of catalytically
active human telomerase from immortal cells. Science.
315:1850–1853. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carpentier C, Lejeune J, Gros F, et al:
Association of telomerase gene hTERT polymorphism and malignant
gliomas. J Neurooncol. 84:249–253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Masutomi K and Hahn WC: Telomerase and
tumorigenesis. Cancer Lett. 194:163–172. 2003. View Article : Google Scholar
|
|
13
|
Kyo S, Takakura M, Fujiwara T and Inoue M:
Understanding and exploiting hTERT promoter regulation for
diagnosis and treatment of human cancers. Cancer Sci. 99:1528–1538.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He X, Qiao Q, Ge N, Nan J, Shen S, Wang Z,
Yang Y and Bao G: Irradiation-induced telomerase activity and
gastric cancer risk: a case-control analysis in a Chinese Han
population. BMC Cancer. 10:312–321. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gandellini P, Folini M, Bandiera R, et al:
Down-regulation of human telomerase reverse transcriptase through
specific activation of RNAi pathway quickly results in cancer cell
growth impairment. Biochem Pharmacol. 73:1703–1714. 2007.
View Article : Google Scholar
|
|
16
|
Nakamura M, Masutomi K, Kyo S, et al:
Efficient inhibition of human telomerase reverse transcriptase
expression by RNA interference sensitizes cancer cells to ionizing
radiation and chemotherapy. Hum Gene Ther. 16:859–868. 2005.
View Article : Google Scholar
|
|
17
|
Natarajan S, Chen Z, Wancewicz EV, Monia
BP and Corey DR: Telomerase reverse transcriptase (hTERT) mRNA and
telomerase RNA (hTR) as targets for downregulation of telomerase
activity. Oligonucleotides. 14:263–273. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
de Souza Nascimento P, Alves G and Fiedler
W: Telomerase inhibition by an siRNA directed against hTERT leads
to telomere attrition in HT29 cells. Oncol Rep. 16:423–428.
2006.PubMed/NCBI
|
|
19
|
Zhang PH, Zou L and Tu ZG: RNAi-hTERT
inhibition hepatocellular carcinoma cell proliferation via
decreasing telomerase activity. J Surg Res. 131:143–149. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dong X, Liu A, Zer C, et al: siRNA
inhibition of telomerase enhances the anti-cancer effect of
doxorubicin in breast cancer cells. BMC Cancer. 9:1332009.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang W and Xing L: RNAi gene therapy of
SiHa cells via targeting human TERT induces growth inhibition and
enhances radiosensitivity. Int J Oncol. 43:1228–1234.
2013.PubMed/NCBI
|
|
22
|
Wang R, Lin F, Wang X, et al: The
therapeutic potential of survivin promoter-driven siRNA on
suppressing tumor growth and enhancing radiosensitivity of human
cervical carcinoma cells via downregulating hTERT gene expression.
Cancer Biol Ther. 6:1295–1301. 2007. View Article : Google Scholar
|
|
23
|
Kurvinen K, Syrjanen S and Johansson B:
Long-term suppression of telomerase expression in HeLa cell clones,
transfected with an expression vector carrying siRNA targeting
hTERT mRNA. Int J Oncol. 29:279–288. 2006.PubMed/NCBI
|
|
24
|
Zhao Y, Ren JL, Zhang R, et al: Study on
apoptosis of human cervical carcinoma HeLa cells with RNA
interference targeting hTERT. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
21:524–526. 2005.(In Chinese).
|
|
25
|
Reynolds A, Leake D, Boese Q, Scaringe S,
Marshall WS and Khvorova A: Rational siRNA design for RNA
interference. Nat Biotechnol. 22:326–330. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
27
|
Kim NW, Piatyszek MA, Prowse KR, et al:
Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lowry OH, Rosebrough NJ, Farr AL and
Randall RJ: Protein measurement with the Folin phenol reagent. J
Biol Chem. 193:265–275. 1951.PubMed/NCBI
|
|
29
|
Ramachandran PV and Ignacimuthu S: RNA
interference as a plausible anticancer therapeutic tool. Asian Pac
J Cancer Prev. 13:2445–2452. 2012. View Article : Google Scholar
|
|
30
|
Blackburn EH: Switching and signaling at
the telomere. Cell. 106:661–673. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boukamp P and Mirancea N: Telomeres rather
than telomerase a key target for anti-cancer therapy? Exp Dermatol.
16:71–79. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Harley CB: Telomerase and cancer
therapeutics. Nat Rev Cancer. 8:167–179. 2008. View Article : Google Scholar
|
|
33
|
Shay JW and Keith WN: Targeting telomerase
for cancer therapeutics. Br J Cancer. 98:677–683. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hahn WC, Counter CM, Lundberg AS,
Beijersbergen RL, Brooks MW and Weinberg RA: Creation of human
tumour cells with defined genetic elements. Nature. 400:464–468.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hahn WC, Stewart SA, Brooks MW, et al:
Inhibition of telomerase limits the growth of human cancer cells.
Nat Med. 5:1164–1170. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lamy E, Goetz V, Erlacher M, Herz C and
Mersch-Sundermann V: hTERT: Another brick in the wall of cancer
cells. Mutat Res. 752:119–128. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Chen H, Li Y and Tollefsbol TO: Strategies
targeting telomerase inhibition. Mol Biotechnol. 41:194–199. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Cong YS, Wright WE and Shay JW: Human
telomerase and its regulation. Microbiol Mol Biol Rev. 66:407–425.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kang SS, Kwon T, Kwon DY and Do SI: Akt
protein kinase enhances human telomerase activity through
phosphorylation of telomerase reverse transcriptase subunit. J Biol
Chem. 274:13085–13090. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kimura A, Ohmichi M, Kawagoe J, et al:
Induction of hTERT expression and phosphorylation by estrogen via
Akt cascade in human ovarian cancer cell lines. Oncogene.
23:4505–4515. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kawagoe J, Ohmichi M, Takahashi T, et al:
Raloxifene inhibits estrogen-induced up-regulation of telomerase
activity in a human breast cancer cell line. J Biol Chem.
278:43363–43372. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ram R, Uziel O, Eldan O, et al: Ionizing
radiation up-regulates telomerase activity in cancer cell lines by
post-translational mechanism via ras/phosphatidylinositol
3-kinase/Akt pathway. Clin Cancer Res. 15:914–923. 2009. View Article : Google Scholar : PubMed/NCBI
|
